Zelira Therapeutics, a company specializing in research, development and commercialization of clinically validated cannabinoid medicines, said its insomnia medication Zenivol has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.
"The formal approval of Zenivol by BfArM in Germany marks a major milestone for Zelira; Germany is one of the largest global markets for cannabinoid-based medicines, and also one of the highest quality global regulatory markets for pharmaceuticals," says Zelira CEO Dr. Oludare Odumosu. "We look forward to working with our partner, Adjupharm, in launching Zenivol in Germany and supporting patients and physicians in treating chronic insomnia in a safe and effective manner. With formal regulatory approval for Zenivol now received in Germany, we continue to progress activities to license Zenivol into other global markets."
